A Stock - Agilent Technologies, Inc.
Unlock GoAI Insights for A
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.95B | $6.51B | $6.83B | $6.85B | $6.32B |
| Gross Profit | $3.64B | $3.54B | $3.46B | $3.72B | $3.41B |
| Gross Margin | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% |
| Operating Income | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B |
| Net Income | $1.30B | $1.29B | $1.24B | $1.25B | $1.21B |
| Net Margin | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% |
| EPS | $4.59 | $4.44 | $4.22 | $4.19 | $3.98 |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | Barclays | Upgrade | Overweight | $165 |
| December 9th 2025 | Goldman | Initiation | Buy | $170 |
| December 2nd 2025 | Morgan Stanley | Initiation | Overweight | $270 |
| October 8th 2025 | Rothschild & Co Redburn | Initiation | Buy | $165 |
| October 8th 2025 | UBS | Upgrade | Buy | $170 |
| February 10th 2025 | Barclays | Upgrade | Equal Weight | $145← $135 |
| August 28th 2024 | Wells Fargo | Initiation | Overweight | $157 |
| July 10th 2024 | Citigroup | Upgrade | Buy | $150← $135 |
| June 27th 2024 | Wolfe Research | Downgrade | Peer Perform | - |
| June 3rd 2024 | Jefferies | Resumed | Hold | $135 |
| April 5th 2024 | Stifel | Upgrade | Buy | $163← $145 |
| December 13th 2023 | Wolfe Research | Initiation | Outperform | $140 |
| December 12th 2023 | BofA Securities | Downgrade | Neutral | $133← $130 |
| November 17th 2023 | UBS | Downgrade | Neutral | $125← $163 |
| September 28th 2023 | Bernstein | Initiation | Market Perform | $123 |
Earnings History & Surprises
AEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 26, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $1.37 | — | — | — |
Q4 2025 | Nov 24, 2025 | $1.58 | $1.59 | +0.4% | ✓ BEAT |
Q3 2025 | Aug 27, 2025 | $1.37 | $1.37 | 0.0% | = MET |
Q2 2025 | May 28, 2025 | $1.26 | $1.31 | +4.0% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $1.28 | $1.31 | +2.3% | ✓ BEAT |
Q4 2024 | Nov 25, 2024 | $1.41 | $1.46 | +3.5% | ✓ BEAT |
Q3 2024 | Aug 21, 2024 | $1.26 | $1.32 | +4.8% | ✓ BEAT |
Q2 2024 | May 29, 2024 | $1.19 | $1.22 | +2.5% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $1.22 | $1.29 | +5.7% | ✓ BEAT |
Q4 2023 | Nov 20, 2023 | $1.34 | $1.38 | +3.0% | ✓ BEAT |
Q3 2023 | Aug 15, 2023 | $1.37 | $1.43 | +4.4% | ✓ BEAT |
Q2 2023 | May 23, 2023 | $1.26 | $1.27 | +0.8% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $1.30 | $1.37 | +5.4% | ✓ BEAT |
Q4 2022 | Nov 21, 2022 | $1.39 | $1.53 | +10.1% | ✓ BEAT |
Q3 2022 | Aug 16, 2022 | $1.20 | $1.34 | +11.7% | ✓ BEAT |
Q2 2022 | May 24, 2022 | $1.12 | $1.13 | +0.9% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $1.18 | $1.21 | +2.5% | ✓ BEAT |
Q4 2021 | Nov 22, 2021 | $1.17 | $1.21 | +3.4% | ✓ BEAT |
Q3 2021 | Aug 17, 2021 | $0.99 | $1.10 | +11.1% | ✓ BEAT |
Latest News
Barclays Upgrades Agilent Technologies to Overweight, Maintains Price Target to $165
📈 PositiveGoldman Sachs Initiates Coverage On Agilent Technologies with Buy Rating, Announces Price Target of $170
📈 PositiveMorgan Stanley Initiates Coverage On Agilent Technologies with Overweight Rating, Announces Price Target of $180
📈 PositiveAshland gains as Standard Investments discloses stake of 5.7%
📈 PositiveCitigroup Maintains Buy on Agilent Technologies, Raises Price Target to $185
📈 PositiveUBS Maintains Buy on Agilent Technologies, Raises Price Target to $180
📈 PositiveWells Fargo Maintains Overweight on Agilent Technologies, Raises Price Target to $175
📈 PositiveJP Morgan Maintains Overweight on Agilent Technologies, Raises Price Target to $180
📈 PositiveA stock has given up its prior loss. Agilent Technologies shares were trading lower after the company reported Q4 financial results and issued Q1 adjusted EPS guidance below estimates.
➖ NeutralBarclays Maintains Equal-Weight on Agilent Technologies, Raises Price Target to $165
➖ NeutralAgilent Technologies shares are trading lower after the company reported Q4 financial results and issued Q1 adjusted EPS guidance below estimates.
📉 NegativeBaird Maintains Outperform on Agilent Technologies, Raises Price Target to $165
📈 PositiveB of A Securities Maintains Neutral on Agilent Technologies, Raises Price Target to $165
➖ NeutralAgilent Technologies Sees Q1 Adj EPS $1.35-$1.38 vs $1.41 Est; Sees Sales $1.790B-$1.820B vs $1.778B Est
➖ NeutralAgilent Technologies shares are trading lower. The company reported Q4 financial results.
📉 NegativeAgilent Technologies Sees FY2026 Adj EPS $5.86-$6.00 vs $5.57 Est; Sees Sales $7.300B-$7.400B vs $6.916B Est
📈 PositiveAgilent Technologies Q4 Adj. EPS $1.59 Beats $1.58 Estimate, Sales $1.861B Beat $1.832B Estimate
📈 PositiveLive On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: Thermo Fisher Scientific, Agilent Technologies"
📈 PositiveAgilent Technologies Appoints Amgen Executive Adam S. Elinoff As CFO, Effective Nov. 17
➖ NeutralTD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $162
📈 PositiveFrequently Asked Questions about A
What is A's current stock price?
What is the analyst price target for A?
What sector is Agilent Technologies, Inc. in?
What is A's market cap?
Does A pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to A for comparison